Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB598 in Advanced Malignancies
NCT05891171Phase 1Active, not recruiting
- Sponsor
- Arcus Biosciences
- Start
- Oct 2023
- Primary completion
- Sep 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of AB598 in advanced cancer, gastric cancer (GC) and gastroesophageal junction cancer (8 arms), sponsored by Arcus Biosciences. Primary endpoints: Adverse Events and Serious Adverse Events at 2 years and Dose-Limiting Toxicities at 2 years. Started Oct 2023; status: active, not recruiting.
02
Drugs
AB598
03
Conditions
advanced cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05891171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891171.